On 27 February, AbbVie and Genmab’s Epkinly (epcoritamab) was granted Priority Review by the FDA for a supplemental biologics licence application (sBLA) for difficult-to-treat relapsed or refractory (r/r) follicular lymphoma (FL), an indolent form of lymphoma, following at least two prior lines of systemic therapy. Despite the availability of new therapies and chimeric antigen receptor (CAR)-T cell therapy, managing r/r FL with effective and more convenient therapies remains a significant unmet need that Epkinly will address.
Epkinly is a subcutaneously administered, bispecific antibody targeting CD3 and CD20 that redirects and activates T-cells to CD20-expressing cancer B-cells, resulting in potent and selective T-cell-mediated cytotoxic activity. Epkinly boasts an FDA and EMA approval in r/r third-line diffuse large B-cell lymphoma (DLBCL) treatment based on robust efficacy data from the Phase I/II EPCORE NHL-1 clinical trial. Epkinly’s sBLA is based on the dose-expansion FL cohort of the EPCORE NHL-1 clinical trial, which demonstrated a high overall response rate (ORR) (82%) and complete response (CR) rate (63%) at the median follow-up of 17.4 months in patients with r/r FL following two or more lines of systemic therapy who were treated with Epkinly. However, the median duration of response was not reached.
Go deeper with GlobalData
Epkinly faces direct competition with Roche’s two FDA-approved bispecific CD20-directed CD3 T-cell engagers, Columvi (glofitamab) and Lunsumio (mosunetuzumab). Columvi and Epkinly were both approved in the third-line DLBCL setting. However, Epkinly generated total global sales of $64m in 2023, while Columvi only generated sales of $29m. In the r/r FL setting, Epkinly will face the first-in-class FDA-approved Lunsumio, which is projected to reach total global sales of $964m by 2029, according to GlobalData’s Analyst Consensus Forecast. Lunsumio has a similar efficacy profile to Epkinly, with an 80% ORR and a 60% CR rate. Lunsumio holds a boxed warning for cytokine release syndrome (CRS), which occurred in 39% of 218 patients, including 15% that were grade 2 and 2% that were grade 3, in the Phase I/II dose escalation study of Lunsumio both as a monotherapy and combined with atezolizumab in patients with r/r B-cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukaemia. Epkinly holds a boxed warning for CRS and immune effector cell-associated neurotoxicity syndrome (ICANS). However, the optimised step-up dose regimen in FL reduced the 67% CRS occurrence of grade 1 (40%), grade 2 (25%), and grade 3 (2%) severity to a 48% occurrence of grade 1 (40%) and grade 2 (8%) events, with no grade 3 severity and no cases of ICANS. These results, which show a mitigation of CRS symptoms, could influence a physician’s decision between the two drugs.
Despite the potential encroachment of third-line DLBCL patient shares and competition with a first-in-class agent in r/r FL, Epkinly’s predicted sales will increase if a second approval is obtained in the r/r FL setting and with potential approvals in earlier-line settings across other B-cell NHL subtypes. Epkinly’s total global sales are predicted to reach $2.3bn, according to GlobalData’s Analyst Consensus Forecast. AbbVie and Genmab are continuing to investigate Epkinly in three ongoing Phase III trials as a monotherapy for patients with r/r DLBCL, in combination with rituximab and lenalidomide for patients with r/rR FL, and in combination with standard-of-care rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for patients with newly diagnosed DLBCL.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
